Nukkleus (NASDAQ:DFNS) Stock Price Down 5.5% – Time to Sell?

Shares of Nukkleus Inc. (NASDAQ:DFNS) traded down 5.5% on Tuesday . The company traded as low as $1.20 and last traded at $1.20. 545,144 shares traded hands during trading, a decline of 76% from the average session volume of 2,314,708 shares. The stock had previously closed at $1.27.

Analysts Set New Price Targets

A number of research firms have commented on DFNS. Wall Street Zen raised Nukkleus from a “sell” rating to a “hold” rating in a report on Sunday, November 23rd. Weiss Ratings reiterated a “sell (d+)” rating on shares of Nukkleus in a report on Wednesday, December 24th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Nukkleus has a consensus rating of “Sell”.

Nukkleus Stock Down 4.5%

The firm has a market cap of $22.71 million, a price-to-earnings ratio of 0.06 and a beta of -6.62. The business has a 50 day moving average of $2.32 and a 200 day moving average of $4.79.

Insider Activity

In related news, insider Anastasiia Kotaieva sold 75,000 shares of the firm’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $4.09, for a total transaction of $306,750.00. Following the sale, the insider owned 75,000 shares in the company, valued at approximately $306,750. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 356,208 shares of company stock worth $1,562,585 over the last quarter. Corporate insiders own 7.90% of the company’s stock.

Hedge Funds Weigh In On Nukkleus

Several institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets acquired a new position in Nukkleus in the second quarter valued at $56,000. Price T Rowe Associates Inc. MD acquired a new stake in Nukkleus during the fourth quarter worth about $57,000. GM Advisory Group LLC purchased a new position in shares of Nukkleus in the 4th quarter worth about $56,000. Millennium Management LLC purchased a new position in shares of Nukkleus in the 4th quarter worth about $60,000. Finally, Ausdal Financial Partners Inc. acquired a new position in shares of Nukkleus in the 3rd quarter valued at about $105,000. 12.47% of the stock is currently owned by institutional investors and hedge funds.

About Nukkleus

Nukkleus Inc, a financial technology company, provides blockchain-enabled technology solutions worldwide. It focuses on providing software and technology solutions for retail foreign exchange trading industry. The company provides transactions platform for dealing and risk management services. It also offers cross-border payment and transactions solutions and blockchain-enabled financial services solutions to institutional investors. In addition, the company provides software, technology, customer sales and marketing, and risk management technology hardware and software solutions.